Previous Close | 0.1600 |
Open | 0.1300 |
Bid | 0.0000 |
Ask | 0.0500 |
Strike | 145.00 |
Expire Date | 2024-05-17 |
Day's Range | 0.0500 - 0.1300 |
Contract Range | N/A |
Volume | |
Open Interest | 2.21k |
Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that its Board of Directors has elected Robert (Rob) B. Carter, a seasoned technology executive, to serve as a director. Including Mr. Carter, the company's Board has 10 members.
Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.75 per share, payable on July 22, 2024 to shareholders of record of Quest Diagnostics common stock on July 8, 2024.
A rise in the use of recreational marijuana use in states that have legalized cannabis appears to be behind a spike in falsified workplace drug tests.